Registration Dossier

Administrative data

Description of key information

Oral
WoE: LD50 oral >2000 mg/kg bw (RA-S, CAS 85116-93-4, Cognis, Potokar 1983, Ac. Tox. oral, RL4)
WoE: LD50 oral >2000 mg/kg bw (RA-S, CAS 68424-31-7, Croda, Robinson, 1991, Ac. Tox. oral, RL4)
WoE: LD50 oral >2000 mg/kg bw (RA-S, CAS 131459-39-7, Croda, Allen, 1999, Acute oral, rat, RL2)
Dermal
LD50 dermal: >2000 mg/kg bw (RA-S, CAS 131459-39-7, Key, Croda, Allen, 1999, acute dermal, rat, RL2)
Inhalation
LD50 inhalation: > 5100 mg/m3 air (aerosol) (RA-S, CAS 68424-31-7, Key, Croda, Parr-Dobrzanski, 1994, acute tox: inhal, rat, RL2)

Key value for chemical safety assessment

Additional information

Acute Oral toxicity:

No study was conducted with the test substance, therefore data of structural analogues were used in a weight of evidence approach. Although two of these studies were conducted with a reduced amount of animals (2 male and 2 female), the results are considered adequate in combination with the other read-across data of the structural analogues in a Weight of Evidence approach.

 

Treatment of rats with 2000 mg/kg bw of CAS 85116-93-4 (WoE, RA-S, CAS 85116-93-4, Cognis, Potokar 1983, Ac. Tox. oral, RL4) revealed the oral LD50 to be higher than 2000 mg/kg bw.

 

The study conducted with CAS No.68424-31-7 (WoE, RA-S, CAS 68424-31-7, Croda, Robinson, 1991, Ac. Tox. oral, RL4) had the same limitations (reduced animal number), but revealed similar results. An initial weight loss was observed after treatment of rats with2000 mg/kg bw, but this effect was completely reversible and the animals showed subsequently normal body weight gain.

Treatment of rats with 2000 mg/kg bw of CAS 131459-39-7 (WoE, RA-S, CAS 131459-39-7, Croda, Allen, 1999, Acute oral, rat, RL2) did not cause adverse effects in a study conducted according to OECD Guideline 423 (Acute Oral toxicity - Acute Toxic Class Method).

Taken together, the available data on acute oral toxicity confirmed that the substance with CAS No. 15834-04-5 is not acute toxic if applied orally.

Acute Dermal toxicity:

The substance with the CAS number 131459-39-7 is a structural analogue of CAS 15834-04-5 and can therefore be used for read-across (RA-S, CAS 131459-39-7, Key, Croda, Allen, 1999, acute dermal, rat, RL2). The semiocclusive application of 2000 mg/kg bw of CAS 131459-39-7 for 24 h (according to OECD 402) did not cause any adverse effects in rats implicating that CAS No. 15834-04-5 is not acute toxic if applied on skin.

 

Acute Inhalation toxicity:

The substance with the CAS No. 68424-31-7 is a structural analogue of CAS No. 15834-04-5 and can therefore be used for read-across (RA-S, CAS 68424-31-7, Key, Croda, Parr-Dobrzanski, 1994, acute tox: inhal, rat, RL2).

Rats were exposed nose only for 4 hours to approx. 5.1 mg/L (analytical concentration of the aerosol of the test material). No mortality occurred and no signs of systemic toxicity were observed. Other effects observed (hunched posture, chromodacryorrhea, piloerection, stains around the nose and wet fur) were reversible. Body weight gain and lung weight were within normal limits and there were no treatment related gross pathological findings.

Justification for classification or non-classification

Taken together in a Weight of Evidence approach,2,2-bis[[(1-oxopentyl)oxy]methyl]propane-1,3-diyl divalerate (CAS No. 15834-04-5) is not acute toxic.

According to the criteria of the CLP and DSD regulation, no classification is warranted.